Merck KGaA
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Belen Garijo Lopez
- Full Time Employees
- 59,020
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Frankfurter Strasse 250 Darmstadt Germany 64293
- IPO Date
- Nov 16, 2007
- Website
- merckgroup.com
- Similar Companies
- Business
- Merck KGaA, Darmstadt, Germany operates as a global science and technology company with core business sectors in Healthcare, Life Science, and Electronics. The company manufactures and markets pharmaceutical and biological prescription drugs targeting oncology, neurology, immunology, fertility, cardiovascular, metabolic, and endocrinological disorders. Its key pharmaceutical products include cancer therapies such as Erbitux (cetuximab), Bavencio, and Mavenclad for multiple sclerosis. The company also develops specialty drugs addressing growth disorders and infertility. In life sciences, Merck offers process solutions, life science services, science and lab solutions, and semiconductor materials, supporting research, manufacturing, and technology innovation. The Electronics sector focuses on semiconductor solutions benefiting from trends like AI and IoT. Headquartered in Darmstadt, Germany, Merck was founded in 1668 and operates globally. Recent major developments include the acquisition of US biopharma SpringWorks Therapeutics in 2025, enhancing Merck’s presence in rare tumors and expanding its U.S. footprint. The company completed acquisition of CN201, a bispecific antibody for B-cell malignancies and autoimmune diseases, expanding its clinical pipeline. Merck also signed a strategic partnership with Caris Life Sciences to discover novel therapeutic targets for antibody-drug conjugates in oncology. In 2025, Merck deepened its digital transformation collaboration with Siemens, focusing on AI and automation in drug discovery and manufacturing. Additionally, Merck plans to acquire ophthalmology-focused EyeBio, advancing its pipeline in retinal diseases. The company continues to invest over €1 billion in mRNA technology manufacturing capabilities, opening new GMP-grade sites in Germany. These strategies underscore Merck’s focus on innovation, external growth, and digital integration across its business sectors.
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Germany's Merck to buy Bio-Techne for $73 per share
Germany's Merck to Buy Bio-Techne for $11 Billion
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
Merck KGaA Q1 Earnings Call Highlights
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck KGaA: Small Breakout In 2026, Followed By Normalization
Short Interest in Merck KGaA (OTCMKTS:MKKGY) Grows By 20.3%
TrumpRx lists many medicines at prices higher than paid in UK
Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript
Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (OTCMKTS:MKKGY) Short Interest Update
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO